Biodiversity Amendment Bill – Impact on the Pharma and Healthcare Industry

Published On: 08/08/2023

Practice Area: Government & Regulatory

Authors:

With the resurgence of ayurveda (now at a global level) and renewed interest in nutraceuticals and supplements that are more ‘natural’ in origin, there was a growing demand for biological resources, along with a shift in focus on sustainable farming and effective management of biological resources. While the state is tasked with honourin commitments towards the CBD and the Nagoya Protocol, the government has to crea environment that is conducive for the pharma and healthcare industries given their economic and strategic importance.